- Home
- DXCM vs TCOM Comparison
DXCM vs TCOM Comparison
Compare DXCM & TCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXCM | TCOM |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.4B | 29.3B |
| IPO Year | 2005 | 2003 |
Fundamental Metrics
Financial Performance| Metric | DXCM | TCOM |
|---|---|---|
| Price | $86.72 | $39.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 8 |
| Target Price | ★ $85.33 | $78.75 |
| AVG Volume (30 Days) | ★ 3.6M | 2.6M |
| Earning Date | 04-30-2026 | 05-18-2026 |
| Dividend Yield | N/A | ★ 0.57% |
| EPS Growth | ★ 47.18 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.46 | $15.73 |
| Revenue Next Year | $12.31 | $13.00 |
| P/E Ratio | $72.20 | ★ $9.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.11 | $38.04 |
| 52 Week High | $92.59 | $79.00 |
Technical Indicators
Market Signals| Indicator | DXCM | TCOM |
|---|---|---|
| Relative Strength Index (RSI) | 46.15 | 28.77 |
| Support Level | $62.02 | $38.04 |
| Resistance Level | $92.46 | $47.07 |
| Average True Range (ATR) | 2.23 | 0.82 |
| MACD | -1.22 | -0.61 |
| Stochastic Oscillator | 24.89 | 10.45 |
Price Performance
Historical ComparisonAbout DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
About TCOM Trip.com Group Limited
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 79% of sales from accommodation reservations and transportation ticketing in 2024. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international travel, which is important to its margin expansion. Most of sales come from its domestic platform, but the company is expanding its overseas business. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.